

Rintaro Hashizume

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6880610/publications.pdf>

Version: 2024-02-01

83
papers

4,536
citations

136885

32
h-index

106281

65
g-index

84
all docs

84
docs citations

84
times ranked

6999
citing authors

#	ARTICLE	IF	CITATIONS
1	A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis. <i>Acta Neuropathologica Communications</i> , 2022, 10, 47.	2.4	11
2	Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 715-726.	1.9	11
3	A novel mouse model of diffuse midline glioma initiated in neonatal oligodendrocyte progenitor cells highlights cell-of-origin dependent effects of H3K27M. <i>Glia</i> , 2022, 70, 1681-1698.	2.5	15
4	Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma. <i>Clinical Cancer Research</i> , 2021, 27, 1766-1777.	3.2	38
5	Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma. <i>Neuro-Oncology</i> , 2021, 23, 1348-1359.	0.6	12
6	The effects of palbociclib in combination with radiation in preclinical models of aggressive meningioma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab085.	0.4	10
7	Fifteen-year trends and differences in mortality rates across sex, age, and race/ethnicity in patients with brainstem tumors. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab137.	0.4	2
8	ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3K27M Mutant Diffuse Intrinsic Pontine Glioma. <i>Neurosurgery</i> , 2020, 86, 742-751.	0.6	8
9	Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG. <i>Cell Reports</i> , 2020, 33, 108286.	2.9	39
10	LSD1 inhibition in pHGG: the key to unleashing immunotherapy?. <i>Neuro-Oncology</i> , 2020, 22, 1237-1238.	0.6	1
11	Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma. <i>Clinical Cancer Research</i> , 2020, 26, 3319-3332.	3.2	44
12	Convection-Enhanced Delivery of Enhancer of Zeste Homolog-2 (EZH2) Inhibitor for the Treatment of Diffuse Intrinsic Pontine Glioma. <i>Neurosurgery</i> , 2020, 87, E680-E688.	0.6	11
13	HGG-26. H3G34V MUTATION AFFECTS GENOMIC H3K36 METHYLATION IN PEDIATRIC GLIOMA. <i>Neuro-Oncology</i> , 2020, 22, iii348-iii348.	0.6	0
14	DDEL-11. CONVECTION-ENHANCED DELIVERY OF EZH2 INHIBITOR FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2020, 22, iii285-iii286.	0.6	0
15	DDRE-15. THE COMBINATION THERAPY OF PARP INHIBITOR AND TMZ IN DIFFUSE MIDLINE GLIOMA HARBORING H3 K27M-MUTANT. <i>Neuro-Oncology</i> , 2020, 22, ii64-ii64.	0.6	0
16	Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas. <i>Cancer Research</i> , 2019, 79, 4026-4041.	0.4	16
17	Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma. <i>Clinical Cancer Research</i> , 2019, 25, 5572-5583.	3.2	52
18	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. <i>Neuro-Oncology</i> , 2019, 21, 901-910.	0.6	184

#	ARTICLE	IF	CITATIONS
19	DIPG-11. ACTIVATION OF RAS SIGNALING AND DISTINCT MITOGEN-ACTIVATED PROTEIN KINASES (MAPKS) PROVIDES UNIQUE THERAPEUTIC VULNERABILITIES IN MUTANT HISTONE DIPG. <i>Neuro-Oncology</i> , 2019, 21, ii70-ii70.	0.6	0
20	HGG-10. HISTONE H3K34V MUTATION IS SUFFICIENT TO DRIVE DISTINCT GENOMIC H3K36 METHYLATION PATTERNS IN PEDIATRIC GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, ii88-ii89.	0.6	0
21	IMMU-01. NOVEL RNA-TARGETING STRATEGY FOR TREATING T CELL-DRIVEN IMMUNOSUPPRESSION IN HUMAN DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, ii92-ii93.	0.6	2
22	Global Reduction of H3K4me3 Improves Chemotherapeutic Efficacy for Pediatric Ependymomas. <i>Neoplasia</i> , 2019, 21, 505-515.	2.3	9
23	Potent Antineoplastic Effects of Combined PI3K±MKNK Inhibition in Medulloblastoma. <i>Molecular Cancer Research</i> , 2019, 17, 1305-1315.	1.5	10
24	Molecular and translational advances in meningiomas. <i>Neuro-Oncology</i> , 2019, 21, i4-i17.	0.6	92
25	MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas. <i>Frontiers in Oncology</i> , 2019, 9, 1568.	1.3	18
26	New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model. <i>Journal of Neuro-Oncology</i> , 2018, 136, 475-484.	1.4	22
27	NIMG-73. RADIOMICS OF GLIOBLASTOMA FOR PREDICTING MGMT PROMOTOR METHYLATION STATUS AND PROGNOSIS. <i>Neuro-Oncology</i> , 2018, 20, vi192-vi192.	0.6	1
28	PDTM-10. NOVEL RNA-TARGETING STRATEGY FOR TREATING T CELL-DRIVEN IMMUNOSUPPRESSION IN HUMAN DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2018, 20, vi205-vi206.	0.6	0
29	DIPG-33. NEW THERAPEUTIC APPROACH FOR BRAINSTEM GLIOMA: INTRANASAL DELIVERY OF NANOLIPOSOMAL SN-38. <i>Neuro-Oncology</i> , 2018, 20, i55-i55.	0.6	1
30	DIPG-63. RADIATION DNA DAMAGE REPAIR INHIBITION BY GSK-J4 INDUCED CHROMATIN COMPACTION IN DIPG. <i>Neuro-Oncology</i> , 2018, 20, i61-i62.	0.6	0
31	EPEN-30. HISTONE H3 LYSINE 4 TRIMETHYLATION IS A POTENTIAL TARGET TO IMPROVE CHEMOTHERAPEUTIC EFFICACY FOR PEDIATRIC PRIMARY EPENDYMOMAS. <i>Neuro-Oncology</i> , 2018, 20, i79-i79.	0.6	0
32	IMMU-24. IMMUNOTHERAPEUTIC NANOTECHNOLOGY TARGETING IDO1 FOR PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2018, 20, i103-i103.	0.6	2
33	PDTM-42. TARGETED INHIBITION OF BET BROMODOMAIN AND JMJD3 PROTEINS FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2018, 20, vi212-vi213.	0.6	0
34	DIPG-05. PRECLINICAL EFFICACY OF MELK INHIBITION IN DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2018, 20, i49-i50.	0.6	0
35	Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced Cancer Therapy. <i>Cell</i> , 2018, 175, 766-779.e17.	13.5	86
36	Measuring Tumor Metabolism in Pediatric Diffuse Intrinsic Pontine Glioma Using Hyperpolarized Carbon-13 MR Metabolic Imaging. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-6.	0.4	12

#	ARTICLE	IF	CITATIONS
37	Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy. <i>Nature Medicine</i> , 2018, 24, 758-769.	15.2	125
38	MELK Inhibition in Diffuse Intrinsic Pontine Glioma. <i>Clinical Cancer Research</i> , 2018, 24, 5645-5657.	3.2	30
39	DIPG-04. INHIBITION OF AXL SENSITIZES DIFFUSE INTRINSIC PONTINE GLIOMA TO CYTOTOXIC THERAPIES. <i>Neuro-Oncology</i> , 2018, 20, i49-i49.	0.6	0
40	CSF H3F3A K27M circulating tumor DNA copy number quantifies tumor growth and in vitro treatment response. <i>Acta Neuropathologica Communications</i> , 2018, 6, 80.	2.4	50
41	Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies. <i>Epigenetics</i> , 2017, 12, 353-369.	1.3	36
42	Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. <i>Nature Medicine</i> , 2017, 23, 493-500.	15.2	332
43	Histone H3.3K27M Represses <i>p16</i> to Accelerate Gliomagenesis in a Murine Model of DIPG. <i>Molecular Cancer Research</i> , 2017, 15, 1243-1254.	1.5	120
44	Therapeutic Hypothesis Testing With Rodent Brain Tumor Models. <i>Neurotherapeutics</i> , 2017, 14, 385-392.	2.1	8
45	A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2. <i>Cell Reports</i> , 2017, 18, 3167-3177.	2.9	32
46	A cytoplasmic COMPASS is necessary for cell survival and triple-negative breast cancer pathogenesis by regulating metabolism. <i>Genes and Development</i> , 2017, 31, 2056-2066.	2.7	55
47	Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas. <i>Journal of Neuro-Oncology</i> , 2017, 131, 495-505.	1.4	29
48	IMMU-46. siRNA APPROACH FOR TARGETING IMMUNOSUPPRESSIVE IDO1 IN PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2017, 19, vi122-vi123.	0.6	0
49	DIPG-36. NOVEL THERAPEUTIC APPROACHES USING NANOLIPOSOMAL SN-38 FOR THE TREATMENT OF HUMAN BRAINSTEM GLIOMA. <i>Neuro-Oncology</i> , 2017, 19, iv13-iv13.	0.6	0
50	SCDT-20. NEW THERAPEUTIC APPROACH FOR BRAINSTEM GLIOMA: INTRANASAL DELIVERY OF NANOLIPOSOMAL SN-38. <i>Neuro-Oncology</i> , 2017, 19, vi269-vi269.	0.6	0
51	Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma. <i>Neurologia Medico-Chirurgica</i> , 2017, 57, 331-342.	1.0	36
52	DIPG-28. RADIATION DNA DAMAGE REPAIR INHIBITION BY GSK-J4 INDUCED CHROMATIN COMPACTION IN DIPG. <i>Neuro-Oncology</i> , 2017, 19, iv10-iv11.	0.6	0
53	Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma. <i>Oncotarget</i> , 2017, 8, 111190-111212.	0.8	26
54	Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. <i>Neuro-Oncology</i> , 2016, 18, now106.	0.6	73

#	ARTICLE	IF	CITATIONS
55	BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas. <i>Clinical Cancer Research</i> , 2016, 22, 5312-5321.	3.2	39
56	Bioluminescence Imaging of an Immunocompetent Animal Model for Glioblastoma. <i>Journal of Visualized Experiments</i> , 2016, , e53287.	0.2	7
57	Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. <i>Journal of Neuro-Oncology</i> , 2016, 126, 385-393.	1.4	31
58	Mutations in chromatin machinery and pediatric high-grade glioma. <i>Science Advances</i> , 2016, 2, e1501354.	4.7	69
59	Imidazoquinolines: Recent Developments in Anticancer Activity. <i>Mini-Reviews in Medicinal Chemistry</i> , 2016, 16, 309-322.	1.1	17
60	Patient-derived Tumor Models for Diffuse Intrinsic Pontine Gliomas. <i>Current Neuropharmacology</i> , 2016, 15, 98-103.	1.4	12
61	Future Clinical Trials in DIPG: Bringing Epigenetics to the Clinic. <i>Frontiers in Oncology</i> , 2015, 5, 148.	1.3	50
62	EAG2 potassium channel with evolutionarily conserved function as a brain tumor target. <i>Nature Neuroscience</i> , 2015, 18, 1236-1246.	7.1	74
63	Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells. <i>Cancer Research</i> , 2015, 75, 5355-5366.	0.4	33
64	Stable luciferase expression does not alter immunologic or in vivo growth properties of GL261 murine glioma cells. <i>Journal of Translational Medicine</i> , 2014, 12, 345.	1.8	21
65	Targeting Wee1 for the treatment of pediatric high-grade gliomas. <i>Neuro-Oncology</i> , 2014, 16, 352-360.	0.6	102
66	Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. <i>Nature Medicine</i> , 2014, 20, 1394-1396.	15.2	411
67	Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor models. <i>Nanomedicine</i> , 2013, 8, 1913-1925.	1.7	22
68	Expression of miR-124 inhibits growth of medulloblastoma cells. <i>Neuro-Oncology</i> , 2013, 15, 83-90.	0.6	59
69	The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. <i>Genes and Development</i> , 2013, 27, 985-990.	2.7	570
70	Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. <i>Genes and Development</i> , 2012, 26, 1780-1796.	2.7	68
71	Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment. <i>Journal of Neuro-Oncology</i> , 2012, 110, 305-313.	1.4	66
72	Cooperative interactions of BRAF ^{V600E} kinase and <i>CDKN2A</i> locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 8710-8715.	3.3	77

#	ARTICLE	IF	CITATIONS
73	An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing. <i>Journal of Neuro-Oncology</i> , 2012, 108, 29-35.	1.4	51
74	Targeted Therapy for <i>BRAFV600E</i> Malignant Astrocytoma. <i>Clinical Cancer Research</i> , 2011, 17, 7595-7604.	3.2	143
75	A human brainstem glioma xenograft model enabled for bioluminescence imaging. <i>Journal of Neuro-Oncology</i> , 2010, 96, 151-159.	1.4	56
76	Identification of Internalizing Human Single-Chain Antibodies Targeting Brain Tumor Sphere Cells. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2131-2141.	1.9	37
77	Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing. <i>Neuro-Oncology</i> , 2010, 12, 366-376.	0.6	23
78	Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models. <i>Journal of Visualized Experiments</i> , 2010, , .	0.2	22
79	Telomerase inhibitors for the treatment of brain tumors and the potential of intranasal delivery. <i>Current Opinion in Molecular Therapeutics</i> , 2010, 12, 168-75.	2.8	6
80	New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. <i>Neuro-Oncology</i> , 2008, 10, 112-120.	0.6	126
81	The RING Heterodimer BRCA1-BARD1 Is a Ubiquitin Ligase Inactivated by a Breast Cancer-derived Mutation. <i>Journal of Biological Chemistry</i> , 2001, 276, 14537-14540.	1.6	576
82	C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. <i>Oncogene</i> , 2000, 19, 4864-4875.	2.6	106
83	A CASE OF DUODENAL AND JEJUNALCOLIC FISTULAS DUE TO OF THE TRANSVERS COLON. <i>The Journal of the Japanese Practical Surgeon Society</i> , 1993, 54, 725-729.	0.0	1